As per the latest report by IMARC Group, titled "Immunoglobulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028," the global immunoglobulin market size reached US$ 14.7 Billion in 2022. Immunoglobulin, also known as antibodies, are proteins made by the immune system against foreign substances, such as bacteria, viruses, and toxins. They are made by specialized cells in the immune system called B cells. When an antigen is detected, B cells are activated and produce immunoglobulins that are specific to that antigen. They are then released into the bloodstream and travel throughout the body to fight the infection. The primary structure of an immunoglobulin molecule consists of two heavy and light chains. Each chain has a variable region that is specific to the antigen it recognizes. There are five main types of immunoglobulins, namely IgG, IgM, IgA, IgD, and IgE, each with a different function and distribution in the body. Immunoglobulin therapy involves using purified immunoglobulin to treat various medical conditions, including immune deficiencies, autoimmune diseases, and neurological disorders. It is typically administered intravenously and has a high safety profile with minimal side effects.
Global Immunoglobulin Market Trends:
The global market for immunoglobulins is witnessing significant growth due to various factors, including rapid urbanization and busy schedules. Moreover, the increasing number of patients with medical conditions, such as multiple myeloma, Waldenstrom macroglobulinemia, and autoimmune disorders, and the rising awareness about early diagnosis are bolstering the market growth. Furthermore, the shifting preference toward personalized medicines and improving healthcare infrastructure are creating a positive outlook for the market. The recent COVID-19 outbreak has surged the demand for hyperimmune globulin as an effective medicine in managing the infection, which is further driving the market growth. In line with this, several pharmaceutical companies are introducing new and advanced immunoglobulins with improved efficiency for treating neurological disorders, which is fueling the market growth. Additionally, the increasing funding for research and development (R&D) projects and rapid technological advancements are propelling the market growth. Looking forward, the market value is projected to reach US$ 21.1 Billion by 2028, expanding at a CAGR of 6% during 2023-2028.
- By the product, the market is divided into IgG, IgA, IgM, IgE, and IgD.
- Based on the application, the market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency disease, myasthenia gravis, and others.
- On the basis of the mode of delivery, the market is bifurcated into intravenous and subcutaneous mode of delivery.
- Based on the region, the market has been segmented into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
- The competitive landscape of the industry has also been examined with some of the key players being ADMA Biologics Inc., Baxter international Inc., Biotest AG, CSL Limited, Grifols S.A, Kedrion S.p.A, LFB SA, Octapharma AG, Sanquin Plasma Products B.V. and Takeda Pharmaceutical Company Limited.
|Base Year of the Analysis
||Product, Application, Mode of Delivery, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||ADMA Biologics Inc., Baxter international Inc., Biotest AG, CSL Limited, Grifols S.A, Kedrion S.p.A, LFB SA, Octapharma AG, Sanquin Plasma Products B.V. and Takeda Pharmaceutical Company Limited
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800